Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib
A systematic review

Fuming Xie, MMa, Weidong Xiao, PhD, MDb, Yahui Jiang, MMa, Xiao Xia, MMa, Yaxu Wang, PhD, MDa,*

Abstract
Background: A large number of studies have shown that KIT mutations are closely related to the prognosis of gastrointestinal stromal tumors (GISTs). At the same time, sunitinib (SU) has become the second-line recommended drug for GISTs because of its efficacy. We initiated a systematic review to compare the efficacy of SU after failure of Imatinib (IM) in different KIT mutations.

Methods: We searched for SU-treated patients with advanced GISTs after failed IM treatment by using databases such as PubMed, EMBASE, and the Cochrane Library, up to March 2018. We conducted statistical analyses to calculate the odds ratio (OR), hazard ratio (HR), and 95% confidence interval (CI) using fixed-effects and random-effects models by Review Manager 5.3 software.

Results: We included a total of 474 patients from 3 retrospective studies and 2 cohort studies. Patients with exon 9 mutations had higher clinical benefit (OR = 2.61, 95% CIs = 1.32–5.18, P = .006) rates and longer progression-free survival (progressive disease, HR = 0.51, 95% CIs = 0.36–0.72, P = .0001) compared with exon 11, but there was no statistically significant difference in overall survival (OS, HR = 0.93, 95% CIs = 0.34–2.55, P = .89) and there was greater heterogeneity (Tau² = 0.72, Chi² = 21.45, df = 3, P < .001, I² = 86%). Subgroup analysis suggests that race may be one of the sources of heterogeneity.

Conclusion: The results show that efficacy of SU is closely associated with KIT genotypes in GISTs. Moreover, racial factor also directly affects the prognosis of different KIT mutational status, so GISTs patients of different genotypes might also consider the use of targeted drugs in consideration of ethnic differences.

Abbreviations: CB = clinical benefit, CI(s) = confidence interval(s), CR = complete response, GISTs = gastrointestinal stromal tumors, HR = hazard ratio, IM = imatinib, M/F = male/female, N/A = not available, OS = overall survival, PD = progressive disease, PDGFRA = platelet-derived growth factor receptor alpha, PFS = progression-free survival, PR = partial response, SD = stable disease, SU = sunitinib.

Keywords: gastrointestinal stromal tumors, imatinib, KIT mutation, sunitinib, systematic review

1. Introduction
Gastrointestinal stromal tumors (GISTs) are a common primary sarcoma in the gastrointestinal tract, accounting for nearly 2% of all gastrointestinal tumors.[1,1] The biological behavior of GISTs varies, which is related to the tumor size and mitotic rate. The majority of GISTs contain an activating mutation in gene encoding KIT or platelet-derived growth factor receptor alpha (PDGFRA) receptor tyrosine kinase.[2,3] Roughly speaking, 95% of the GISTs would express cell-surface transmembrane receptor KIT with tyrosine kinase activity.[4,1] The resulting abnormal receptor tyrosine kinases are superior targets for treatment with tyrosine kinase inhibitors. A large amount of researches have shown that tumor survival, angiogenesis, and resistance to antitumor treatment are derived from mutations of KIT.[4,6]

Currently, advanced or metastatic GISTs remain a huge challenge which resists general chemotherapy. Imatinib (IM) which is a selective inhibitor of KIT and PDGFRα and it is also the first tyrosine kinase inhibitor (TKI) approved for the therapy of advanced GISTs.[7,1] IM is considered a standard first-line therapy for its beneficial effects to advanced GISTs. However, the
clinical benefits observed in GISTs patients with IM vary according to KIT and PDGFRα genotype.8–10 A number of multicenter trials have compared the prognosis of IM treatment with different advanced GISTs genotypes, and Demetri’s study reported that mutations of the KIT gene in GISTs occur most frequently in KIT exon 11, followed by those in KIT exon 9, and tumors containing deletions in the KIT exon 11 are clinically more aggressive than tumors with other types of mutations.11–12 Resistance and intolerance to IM is one of serious problems in practical use.13 About 5% to 14% of GISTs patients show evidence of primary resistance to IM.14 Even high doses of IM frequently do not significantly improve the prognosis.15 Sunitinib (SU) is another small-molecule TKI that selectively targets KIT and PDGFRα, all 3 isoforms of vascular endothelial growth factor receptor, FMS-like tyrosine kinase 3, colony-stimulating factor 1 receptor, and glial cell line-derived neurotrophic factor receptor (rearranged during transfection).16 International, randomized, double-blind Phase III clinical trials have demonstrated the clinical benefit of SU in patients with IM resistance or intolerance to failure in advanced GISTs, which led to the approval of SU as a second-line therapy for GISTs in many countries.17 Similarly, clinical benefit has a relationship with SU-treated patients with GISTs is thought to be influenced by mutational status. Like the other inhibitors of tyrosine kinase, SU works by means of targeting certain constitutive activated sites of tyrosine kinase caused by gain-of-function mutations.18,19 Considering of the lack of large-sample, multi-center clinical RCTs, the potential predictive value of KIT mutation on the efficacy of SU against GISTs after failure of IM therapy remains obscure. Although, it is essential to predict the mutation’s response to prognosis after treatment of SU.

In the present study, we performed a systematic review on patients treated with SU after failed IM treatment to analyze and summarize the clinical effect and prognostic value of genotypes of KIT exon 9 and exon 11 mutational status in GISTs.

2. Materials and methods

Ethical approval or patient consent was not required due to the present study is a review of previously published literatures.

2.1. Searching strategy

Our present study was shown related results in adherence to the PRISMA statement.20 This study was used medical subject headings and keywords to search comprehensively in databases such as PubMed, EMBASE, and Cochrane library was conducted up to March 2018. We used the following keywords: “Gastrointestinal Stromal Tumors,” “Imatinib Mesylate,” “Sunitinib.” The searching fields for these terms are set to: title/abstract. These terms were contacted by “AND” or “OR.” Only published studies of English full-text articles on human subjects could be included. Other than this, we also searched for the reference of included articles and relevant reviews manually. We contacted a part of authors to acquire complete raw data information if necessary.

2.2. Inclusion and exclusion criteria

Our inclusion criteria were as follows:

(1) subjects were patients diagnosed with advanced GISTs, without other malignant tumors;
(2) SU was used as a treatment after failure with IM treatment;
(3) without chemotherapy, or have ended chemotherapy for more than 4 weeks;
(4) the pathological data was complete, and primary tumor tissues were obtained for c-KIT mutations;
(5) clinical outcomes included the following outcomes: complete response (CR), partial response (PR), stable disease (SD), or clinical benefit (CB: defined as the percentage of patients who experienced a CR, PR, or SD lasting at least 24 weeks as per RECIST);
(6) included at least: progression-free survival (PFS) or overall survival (OS), with 95% confidence interval (CI).

The exclusion criteria were:

(1) duplicated publications;
(2) reviews, letters, case report, or comments.
(3) Subjects taking other drugs that may affect outcomes (eg, immunosuppressive agents, etc);
(4) patients concurrently used other treatments during the experiment (eg, surgery, radiofrequency ablation, etc);
(5) incomplete or useless data.

2.3. Data extraction

One investigator performed data extraction while another one checked independently for accuracy. This study extracted following information: author, publication year, study location, study design, sample size, patient age, gender ratio, mutational status, and outcomes (included: PFS, OS, CR, PR, SD, PD, CB). In the survival analysis, some included studies have not published hazard ratio (HR) and 95% CI. Studies must show the definitive number of patients with KIT exon 9 and exon 11 mutation, along with the number of observed GISTs progression or death, so that we are able to achieve mathematical HR approximation by established methods.21 When the vital data has not been published entirely, but a Kaplan–Meier curve was provided, data can extract from the curve by Engauge Digitizer version 10.4.22

2.4. Quality assessment

Two independent investigators performed quality assessment of each included studies. The included cohort and retrospective studies were on the basis of the Newcastle–Ottawa scale. We graded quality in 3 fields which include the selection of research group, group’s comparability, and outcomes or exposure. A score of study at least 5 is considered to be of high quality. Different authors discussed to resolve the discrepancies of quality assessment in the results respectively.

2.5. Statistical analysis

All analysis was performed by Review Manager 5.3 provided by Cochrane Collaboration. Heterogeneity between studies was checked by chi-square test and I². Odds ratio (OR) and HRs with 95% CIs were calculated by fixed or random effect model depending on heterogeneity (a fixed effect model for I² not more than 50%) while a random effect model for I² more than 50%). A systematic review compared the OR of CB and the HR of PFS and OS in c-KIT exon 9 and exon 11 in patients with advanced GISTs using SU after the failure of IM therapy.23 Publication bias was detected by using Funnel plot. One study was removed at a time to assess the resulting stability as a sensitivity analysis. For all analysis, P values less than .05 indicated statistical significance.
3. Results

3.1. Characteristics of the included studies

There were identified 163 articles, 699 articles, and 57 articles, respectively searched from PubMed, EMBASE, and Cochrane Library. A total of 36 citations were thought to be potentially relevant after reviewing titles and abstracts. A total of 10 articles satisfied the eligibility criteria after reading the full text carefully. Finally, 5 studies were included in our systematic review.\textsuperscript{[24–28]}

Literature screening flow was shown in Figure 1. The 5 studies involving 474 patients satisfied the eligibility criteria were reanalyzed in this systematic review. The publication year ranged from 2011 to 2016. The follow-up durations varied among these studies (from 10 to 100 months). The items above are all collected. Their basic characteristics are reported in Table 1.

![Figure 1. Flow diagram of identifying relevant studies.](image)

### Table 1

Characteristics of individual studies included in the meta-analysis.

| Author            | Publication yr | Study location | Study design | Sample size (M/F) | Age, yr median (range) | Mutational status | Follow-up, mo | Outcomes          |
|-------------------|----------------|----------------|--------------|-------------------|------------------------|-------------------|---------------|------------------|
| Reichardt et al\textsuperscript{[20]} | 2016           | Germany        | Retrospective| 230 (139/91)      | 60 (11–83)             | Exon 9, 11        | 58–100       | PFS, OS, CR, PR, SD, PD |
| Yoon et al\textsuperscript{[21]}   | 2012           | Korea          | Cohort       | 88 (55/33)        | 59 (25–76)             | Exon 9, 11        | 19–48        | OS, CR            |
| Li et al\textsuperscript{[22]}     | 2012           | China          | Retrospective| 55 (40/15)        | N/A                    | Exon 9, 11        | 12–15        | PFS, OS, CR, PR, SD, PD |
| Chen et al\textsuperscript{[23]}   | 2011           | Taiwan         | Retrospective| 23 (7/16)         | 59 (24–83)             | Exon 9, 11        | 10–30        | PFS, OS, CR, PR, SD, PD |
| Heinrich et al\textsuperscript{[24]} | 2008           | USA            | Cohort       | 78 (53/25)        | 55 (26–76)             | Exon 9, 11        | 30–54        | PFS, OS          |

\textsuperscript{CB} = clinical benefit, \textsuperscript{CR} = complete response, \textsuperscript{M/F} = male/female, \textsuperscript{N/A} = not available, \textsuperscript{OS} = overall survival, \textsuperscript{PD} = progressive disease, \textsuperscript{PFS} = progression-free survival, \textsuperscript{PR} = partial response, \textsuperscript{SD} = stable disease.
Table 2

| Exposure | Adequate definition | Same method of ascertainment | Case control | Total score |
|----------|---------------------|-----------------------------|--------------|-------------|
|          |                     |                             | A. Adequate   |             |
|          |                     |                             | B. Representativeness |             |
|          |                     |                             | C. Selection of cases and controls |             |
|          |                     |                             | D. Definition of cases |             |
|          |                     |                             | E. Ascertainment of cases |             |
|          |                     |                             | F. Comparability |             |

As for quality assessment, the quality of included 5 studies was generally high; specific data are shown in Table 2.

3.2. Systematic review regarding the efficacy of SU

3.2.1. Clinical benefit. Four studies reported the data of clinical benefit.\cite{24-27} The combined results showed that there was no heterogeneity among 4 studies (\(\chi^2 = 5.14, df = 3, I^2 = 42\%\)), so the fixed effects model did. The difference was statistically significant between KIT exon 9 and exon 11 mutations group (OR = 2.61, 95\% CIs = 1.32–5.18, \(P = .006\)), suggesting that group of exon 9 mutations was able to improve the clinical benefit rate, compared with exon 11 mutations group for advanced GISTs patients after failure of IM therapy (Fig. 2).

3.2.2. Progression-free survival. Four studies reported PFS data included 2 genotypes of KIT exon 9 and exon 11 mutations, involving 73 and 221 cases, respectively.\cite{24-28} The minor heterogeneity was observed among 4 studies (\(\chi^2 = 3.94, df = 3, P = .27, I^2 = 24\%\)), so the fixed effects model was used. The results show that the difference was obvious statistically significant (HR = 0.31, 95\% CIs = 0.36–0.72, \(P = .001\)). It showed that the efficacy of SU in the treatment of KIT exon 9 mutations compared with exon 11-induced GISTs was superior in the PFS rate (Fig. 3A).

3.2.3. Overall survival. Four studies reported OS data included 2 genotypes of KIT exon 9 and exon 11 mutations, involving 78 and 246 cases, respectively.\cite{24-28} Because of significant heterogeneity observed among 4 studies (\(\chi^2 = 21.45, df = 3, P < .001, I^2 = 86\%\)), a random effects model was used. The results showed no statistically significant difference (HR = 0.93, 95\% CIs = 0.34–2.55, \(P = .89\)), suggesting that no mutations of either exon 9 or exon 11, there was no apparent longer OS (Fig. 3B).

3.2.4. Subgroup analysis. Due to the significant heterogeneity of OS in this study, the subgroup analysis was used to explore the source of heterogeneity. The specific results are shown in Figure 4. The subgroup data of OS of Asian and other countries are statistically different respectively. And each subgroup of the heterogeneity is significantly lower (\(I^2 = 0\)). The ethnic differences may be one of the sources of heterogeneity for this research. There was no statistically significant difference in analysis methods, year of publication, the initial dose of IM, or SU dose.

3.2.5. Sensitivity analysis. A sensitivity analysis was performed to explore potential sources of heterogeneity. The pooled ORs of CB for patients with advanced GISTs after the failure of IM therapy in exon 9 and exon 11 were not significantly changed, while the pooled HRs of PFS for patients in KIT exon 9 and exon 11 mutations were not significantly changed, which confirmed the stability of these 2 analyses. One study affected the OS result for patients with advanced GISTs after the failure of IM therapy in exon 9 and exon 11.\cite{25} Consistent with the conclusion that the aforementioned, race may be one of the sources of heterogeneity.

3.2.6. Publication bias. Due to the small number of included studies (\(n = 5\)), the funnel bias was not used for publication bias analysis.

4. Discussion

According to the latest NCCN Clinical Practice Guidelines in Oncology of the GIST, regardless of the limitations or widespread of GISTs for first-line treatment (IM 400 mg/d) after the failure, the program to SU treatment has been changed by 2A.
Recommended for category 1.\textsuperscript{[29,30]} Mutation testing for patients with advanced GISTs has been recommended by NCCN before taking TKIs to predict drug response. Related studies have demonstrated the efficacy of different genotypes of GIST treated with IM. There is a 2.29-fold improvement in cumulative response of KIT exon 11-mutant group compared with exon 9-mutant group. GISTs patients with KIT exon 9 mutations have higher risk of progression than those with exon 11 mutations, and 5-year RFS rate was significantly higher in patients with KIT exon 11 deletion than in those with other types of KIT exon 11 mutations. But there is not consistent suggest for SU in the current studies.\textsuperscript{[31–34]} Therefore, to further evaluate the efficacy of SU treatment on different genotypes of advanced GISTs after failure of IM therapy, we did this systematic review to identify the better reference for the treatment of GISTs patients.

To the best of our knowledge, this is the first systematic review to illustrate a significant benefit from SU therapy for advanced GISTs after failure of IM therapy who harbor a KIT mutation in PFS and OS. More importantly, the present systematic review revealed that clinical benefits of patients with advanced GISTs after failure of IM therapy is associated with types of KIT mutations. Regardless of ethnicity, the overall incidence of clinical benefit and PFS was higher in patients with exon 9 mutations compared to KIT exon 11. We also did a subgroup analysis to demonstrate the possible benefits from SU treatment for advanced GISTs who harbor a KIT mutation in OS in Asian and other people respectively. In Asian group, we found that the OS of GISTs patients with KIT exon 9 mutations was significantly higher than that of patients with KIT exon 11 mutations, and other groups excluding Asians showed the opposite result. It might be that the SU sensitivity of different types of KIT mutations in different populations is different, with the fact that vast majority used standard doses (37.5 mg/d).

It was reported that different mutational subtypes of KIT exon 9 and 11 may have a differential impact on treatment outcome (eg, GISTs with exon 11 deletions are more aggressive than those
collection timings varied between patients in each patient. As a result of this limitation and the fact that biopsy some included studies, in some cases, only 1 biopsy was taken for variables which would affect the efficacy of SU in advanced GISTs, including the kinase mutational status pre- and post-treatment, initial SU dose, pharmacokinetics, pharmacodynamics, adherence to therapy, site of the primary tumor, and metastatic site. At the same time, due to lack of data and other reasons, we have not conducted statistical analysis of adverse events after SU treatment. This result may also have an impact on the final treatment decisions. The incidence rate of different gene mutations is different between the exon 9 and exon 11 group, and the baseline may be inconsistent, which may affect the accuracy of the results of this systematic review. Therefore, additional research in the future, especially larger, prospective, randomized controlled studies, are needed to evaluate the correlation between mutation status of KIT and/or other genes and their clinicopathological significance in SU-induced GISTs patients after first-line treatment failure. Another limitation of our study is that all survival analysis data, especially HR and CI, were extracted from included studies’ results by software, and therefore, individual patient information was lost, and there may be errors with the original information.

SU is currently approved only as second-line therapy for GIST, but studies are being planned to evaluate its efficacy and safety as first-line treatment. And the results of genotyping have become an essential baseline work-up in patients with GIST to predict treatment outcomes and possibly to individualize TKI therapy as a means to maximize clinical efficacy in patients with GIST. The present study may advance understanding of the mechanisms of resistance and may facilitate the development of strategies or therapy to circumvent it.

In conclusion, this systematic review confirms advantages of clinical benefits and PFS of KIT exon 9 mutation group, but as for OS, it could reflect different efficacy through subgroup analysis. In the present study, we first proposed that patients with advanced GISTs after failure of IM in exon 9 mutation had better efficacy with SU than patients with exon 11 mutation in the Asian population. Therefore, determination of differential KIT mutation status is still a potential prognostic marker for GIST patients after failure of IM. For that GISTs is a disease originating from genotype mutations, the biological role and clinical significance of most of the mutation, in GIST pathogenesis and development remain undefined, more high-quality research is required to define better the individualize precision therapy and SU treatment based on tumor genotype characteristics.

Author contributions
F.-M.X. and W.-D.X. contributed equally to this study. F.-M.X. and Y.-X.W. conceived the study idea. X.X. and Y.-H.J. performed literature search, study selection, and data extraction. F.-M.X. performed statistical analyses and interpretation of corresponding results. F.-M.X. drafted the initial manuscript. W.-D.X. proposed valuable suggestions for revising the manuscript and carefully edited the entire manuscript. Y.-X.W. had primarily responsibility for the final content.

Figure 4. Subgroup of forest plot diagrams of hazard ratios of overall survival for patients with advanced GISTs after failure of first-line therapy in exon 9 and exon 11. GISTs = gastrointestinal stromal tumors.
Conceptualization: Fuming Xie, Yaxu Wang.
Formal analysis: Fuming Xie.
Investigation: Yahui Jiang, Xiao Xia.
Methodology: Fuming Xie.
Project administration: Weidong Xiao.
Resources: Yahui Jiang, Xiao Xia.
Software: Fuming Xie.
Supervision: Yaxu Wang.
Validation: Weidong Xiao.
Writing – original draft: Fuming Xie.
Writing – review and editing: Weidong Xiao, Yaxu Wang.
Fuming Xie orcid: 0000-0002-7270-920X.

References
[1] George S, Desai J. Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. Curr Treat Options Oncol 2002;3:489–96.
[2] Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013;382:973–83.
[3] Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors. Science 1998;279:577–80.
[4] Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumours. Ther Adv Med Oncol 2014;6:115–27.
[5] Ammendola M, Sacco R, Sammarco G, et al. Mast cells positive to trypsin and c-kit receptor expressing cells correlates with angiogenesis in gastric cancer patients surgically treated[J]. Gastroenterology Res Pract 2013;2013:1–5.
[6] Stankov K, Popovic S, Mikov M. C-KIT signaling in cancer treatment. Curr Pharm Des 2014;20:2849–80.
[7] Demetri GD, von Mehren M, Blanke CD, et al. Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.
[8] Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011;67 Suppl 1:S23–43.
[9] Emile JF, Tabone-Eglinger S, Theou-Anton N, et al. Prognostic value of KIT exom 11 deletions in GISTs. Gastroenterology 2006;131:976–87.
[10] Xiaofoi Z, Xiaoying Z, Wezhi W, et al. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis[J]. PLoS ONE 2013;8:e79275.
[11] Demetri GD, Garrett CR, Schoffski P, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012;18:3170–9.
[12] Lee JH, Kim Y, Choi JW, et al. Correlation of imatinib resistance with tumor genotype in Korean patients. Invest New Drugs 2012;30:819–27.
[13] Li J, Gao J, Hong J, et al. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumours. Future Oncol 2012;8:617–24.
[14] Chen YY, Yeh CN, Cheng CT, et al. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol 2011;17:2113–9.
[15] Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase gene fusions correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352–9.
[16] Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329–38.
[17] George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumor after imatinib failure. Eur J Cancer 2009;45:1595–68.
[18] Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2005;23:4342–9.
[19] Debrec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2004;40:689–95.
[20] Debrec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093–103.
[21] Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360–7.
[22] Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245–66.
[23] Lasota J, Miettinen M, KIT and PDGFRA mutations in gastrointestinal stromal tumours (GISTs). Semin Diagn Pathol 2006;23:91–102.
[24] Antonescu CR, Besmer P, Gao T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182–90.
[25] Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A 2009;106:1342–7.
[26] Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor c-kit mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009;14:43–9.
[27] Gao J, Jing Z, Tian et al. Secondary mutations of KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumor. Med Oncol 2013;30:1–7.
[28] Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294–9.
[42] Wandelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005;6:249–51.

[43] Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270–9.

[44] Nishida T, Kanda T, Nishitani A, et al. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 2008;99:799–804.

[45] Attili SV, Ananda B, Mandapal T, et al. Factors influencing progression-free survival in gastrointestinal stromal tumors with special reference to pathologic features, cytogenetics, and radiologic response. Gastrointest Cancer Res 2011;4:173–7.

[46] Han D, Deneve J, Gonzalez RJ. Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters. The consequences of tumor rupture. Am Surg 2012;78:74–9.

[47] Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8 Suppl 2:S1–41.